Manfred Kranzinger

Manfred Kranzinger

Auto-generated profile, based on publicly available information

Manfred Kranzinger

Univ.-Klinik für Radiotherapie und Radio-Onkologie, Landeskrankenhaus Salzburg, Univ.-Klinikum der Paracelsus Medizinischen Privatuniversität, Müllner Hauptstr. 48, 5020, Salzburg, Austria.

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2014 in Strahlentherapie und Onkologie
Verified
Journal Article
Closed access
PDF file
MKManfred Kranzinger
Manfred Kranzinger
Franz ZehentmayrFranz Zehentmayr
Franz Zehentmayr
GFGerd Fastner
Gerd Fastner
GOGerhard Oberascher
Gerhard Oberascher
FMFlorian Merz
Florian Merz
FSFelix Sedlmayer
Felix Sedlmayer

28 May 2015 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
Franz ZehentmayrFranz Zehentmayr
Franz Zehentmayr
MSMatthias Söhn
Matthias Söhn
AEAnn-Katrin Exeli
Ann-Katrin Exeli
KWKarl Wurstbauer
Karl Wurstbauer
ATAlmut Tröller
Almut Tröller
FSFelix Sedlmayer
Felix Sedlmayer
One of the primary dose-limiting toxicities during thoracic irradiation is acute esophagitis (AE). The aim of this study is to investigate dosimetric and clinical predictors for AE grade ≥ 2 in patients treated with accelerated radiotherapy for locally advanced non-small cell lung cancer (NSCLC). 66 NSCLC patients were included in the present analysis: 4 stage II, 44 stage IIIA and 18 stage IIIB. All patients received induction chemotherapy followed by dose differentiated accelerated radiotherapy (DART-bid). Depending on size (mean of three perpendicular diameters) tumors were binned in four dose groups: 6 cm 90 Gy. Patients were treated in 3D target splitting technique. In order to estimate the normal tissue complication probability (NTCP), two Lyman models and the cutoff-logistic regression model were fitted to the data with AE ≥ grade 2 as statistical endpoint. Inter-model comparison was performed with the corrected Akaike information criterion (AICc), which calculates the model’s quality of fit (likelihood value) in relation to its complexity (i.e. number of variables in the model) corrected by the number of patients in the dataset. Toxicity was documented prospectively according to RTOG. The median follow up was 686 days (range 84–2921 days), 23/66 patients (35 %) experienced AE ≥ grade 2. The actuarial local control rates were 72.6 % and 59.4 % at 2 and 3 years, regional control was 91 % at both time points. The Lyman-MED model (D50 = 32.8 Gy, m = 0.48) and the cutoff dose model (Dc = 38 Gy) provide the most efficient fit to the current dataset. On multivariate analysis V38 (volume of the esophagus that receives 38 Gy or above, 95 %-CI 28.2–57.3) was the most significant predictor of AE ≥ grade 2 (HR = 1.05, CI 1.01–1.09, p = 0.007). Following high-dose accelerated radiotherapy the rate of AE ≥ grade 2 is slightly lower than reported for concomitant radio-chemotherapy with the additional benefit of markedly increased loco-regional tumor control. In the current patient cohort the most significant predictor of AE was found to be V38. A second clinically useful parameter in treatment planning may be MED (mean esophageal dose).

1 August 2007 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
KWKarl Wurstbauer
Karl Wurstbauer
HDHeinz Deutschmann
Heinz Deutschmann
PKPeter Kopp
Peter Kopp
FMFlorian Merz
Florian Merz
MKManfred Kranzinger
Manfred Kranzinger
FSFelix Sedlmayer
Felix Sedlmayer